Golden
Cala Health

Cala Health

A medical technology company developing neuroperipheral therapy, a new class of electrical medicine aimed at treating chronic disease with wearable electronics.

Neuroperipheral therapy stimulates peripheral nerves with body-worn electronics and has the potential to treat chronic diseases non-invasively. Cala Health is working on a treatment for Essential Tremor (ET), a movement disorder that makes it difficult to perform daily activities like eating and writing. Cala Health supports the International Essential Tremor Foundation (IETF). 

Products

Their Cala One device achieved FDA clearance in April 2018 for transient relief in adults of ET. In December 2018, Cala Health launched a clinical trail for its wrist-worn neurostimulator in treatment of ET. The clinical trial has 500 patients in a single-arm Prospect trial which will evaluate the Cala Two device at relieving symptoms for three months, with treatments twice per day at 40 minutes each. 



Cala Trio is Cala Health's lead product as of 2019.Interim results from a clinical study called the PROSPECT trial where the Cala Trio device was used were reported in 2019 at the International Congress of Parkinson's Disease and Movement Disorders, in Nice, France. It was shown that the Cala Trio device, when used for 40 minutes twice daily, effectively helped reduce hand tremors within three months. The device stimulates the nerves responsible for tremor and is calibrated to each patient’s hand tremor. 62% of trial participants had their tremors improve from severe to moderate or from mild to slight. Quality of life was also reported to be improved. 18% of participants experienced transient device-related adverse events which included wrist discomfort, skin irritation and pain. The Cala Trio device has U.S. FDA clearance and is available by prescription in select U.S. markets.

Leadership

Cala Health’s former CEO Kate Rosenbluth was replaced by Renee Ryan in September 2019. Ryan was previously VP of venture investments at Johnson & Johnson Innovation where she led the firm’s investment in Cala’s Series A round and 15 other investments. 



Timeline

People

Name
Role
LinkedIn

Chris Daniel

VP, Commercial Operations



John Colombo

VP of Product Development and Operations



Kate Rosenbluth, PhD

former CEO



Kristie Burns

Chief Marketing Officer



Manish Gupta

VP of Clinical Affairs



Renee Ryan

CEO



Scott Wilson, PhD

VP of Quality Assurance and Regulatory Affairs



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References